We are looking for a few select pharma partners to work with us over the next 12 months in spearheading the advancement of this new alternative to biological indicators. Enzyme Indicators represent a multi-million pound investment – currently protected globally by in excess of thirty patents. As part of continued research into Enzyme Indicators (EIs), Protak Scientific, working with Public Health England (PHE) has commissioned a further study. Over the next 12 months Protak and PHE will be working with only five selected pharmaceutical partners in trialing EIs in a manufacturing environment. These partners will gain invaluable insight, insider knowledge and will benefit from initially exclusive access to Protak’s data centres.
We’ll leave it to the pharma Financial Directors to work out the savings to be made in man-hours and by avoiding product recalls and providing instant assured product release. For the Quality Directors EIs offer complete assurance and peace-of-mind, satisfying that the process is continually monitored and verified; providing the very first immediate verification tool available. This quantifiable data with pre-emptive knowledge can provide an early warning. The absolute purity of this data vs traditional biological indicators makes this technology such a revelation. The first trial partner is already benefitting from the cutting-edge technology – with other companies in negotiations. To become a Protak partner – please get in touch